WuXi AppTec stock: Morgan Stanley keeps HKD 207.40 target for WuXi AppTec stock
Published on 10/20/2026 at 16:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- Morgan Stanley kept its HKD 207.40 target and Overweight rating on October 15, 2026.
- Third-quarter revenue is estimated at HKD 18.10 billion for October 26, 2026.
- WuXi AppTec stock costs EUR 22.32 at Lang & Schwarz on October 20, 2026 at 4:04 p.m. CEST.
Morgan Stanley kept its Overweight rating and HKD 207.40 target for WuXi AppTec on October 15, 2026, according to Futunn. The report also described planned capacity expansion at WuXi STA and cited 2026 capital expenditure guidance of RMB 7.50 billion to RMB 8.50 billion. WuXi AppTec stock was trading at EUR 22.32 at Lang & Schwarz on October 20, 2026 at 4:04 p.m. CEST.
Results date carries the next test
WuXi AppTec is expected to publish its third-quarter results on October 26, 2026. Estimates compiled by Moomoo put third-quarter revenue at HKD 18.10 billion and net income at HKD 5.40 billion. The estimates were based on one analyst.
First-half growth sets a high bar
The company reported RMB 28.90 billion in revenue for the first half of 2026, an increase of 38.93 percent from the first half of 2025. Net profit rose 34 percent in the same period, while the company raised its full-year performance guidance. These figures were presented on the company's investor-relations page, which also identifies WuXi AppTec as an integrated contract research, development, and manufacturing organization serving pharmaceutical and life sciences customers.
Shanghai quote offers separate context
On the Shanghai Stock Exchange, WuXi AppTec last traded at CNY 146.50 on October 19, 2026. The company also trades in Hong Kong under ticker 2359, while its Frankfurt listing uses ticker WX8. The home-market listing and ISIN assignment are identified by El Fondo.
What the target means for valuation
Morgan Stanley's HKD 207.40 target is a company-specific reference for the Hong Kong-listed shares, not a euro price. Its report linked the valuation to expansion plans, including an intended increase in small-molecule reactor capacity from 4,000 to 5,000 cubic meters and solid-phase peptide synthesis capacity from 100,000 liters to 130,000 liters during 2026.
Stock stays tied to execution
The investor case now combines a dated analyst target with a near-term reporting event and a strong first-half comparison. The key numerical test is whether third-quarter revenue can approach the HKD 18.10 billion estimate while the company executes its expanded capacity plans. WuXi AppTec was trading at EUR 22.32 at Lang & Schwarz on October 20, 2026 at 4:04 p.m. CEST.
The further course of trading is shown by the continuously updated real-time quote of WuXi AppTec stock.
WuXi AppTec at a glance
- Company: WuXi AppTec Co., Ltd.
- ISIN: CNE100003F19
- Ticker: 2359
- Primary exchange: Hong Kong Stock Exchange
- Price Lang & Schwarz (as of October 20, 2026, 4:04 p.m. CEST): EUR 22.32
- Sector / Industry: Healthcare / Medical diagnostics and research
Market context: Current market reports.
